Drs. Doug Devries, Marc Bloomenstein, and Cecelia Koetting discuss strategies to manage presbyopes from early to late stages of presbyopia progression. Learn about new and emerging pharmaceutical treatments options as well as next-generation presbyopia-correcting IOLs.
Supported by unrestricted educational grants from Johnson & Johnson Vision and Acufocus.
Upon completion of this activity, the participant should be able to:
Sponsored by: 
Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator.
This activity, COPE Activity Number 123848, is accredited by COPE for continuing education for optometrists. This course is approved for 1.25 hours of CE.
Course #: 78203-PO
Activity #: 123848
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Douglas K. Devries, OD
Co-founder
Eye Care Associates of Nevada
Sparks, NV
Marc R. Bloomenstein, OD, FAAO
Schwartz Laser Eye Center
Director of Optometric Services
Scottsdale, AZ
Cecelia C. Koetting, OD, FAAO
Hines Sight
Denver, CO
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Douglas K. Devries, OD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant/Speaker’s Bureau: Akorn, Alcon, Allergan, Avellino, Azura, Bausch + Lomb, Bio Tissue, BlephEx, Bruder, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Lumenis, Novartis, OcuSoft, Ophthalmic Resource Partner, Quidel, Science Based Health, Sight Sciences, Sun Pharmaceutical Industries, Tarsus, TearLab, Thea, and Visus. Share/Stockholder: RPS.
Marc R. Bloomenstein, OD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Aerie Pharmaceuticals, Allergan, Azura, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OcuSoft, Sight Sciences, Sun Pharmaceutical Industries, and Tarsus. Grant/Research Support: Sight Sciences. Speaker’s Bureau: Allergan, Bausch + Lomb, Johnson & Johnson Vision, Kala Pharmaceuticals, OysterPoint, RVL, Sight Sciences, and Sun Pharmaceutical Industries.
Cecelia C. Koetting, OD, FAAO, has had a financial agreement or affiliation during the past year with the following ineligible companies in the form of Consultant: Alcon, Glaukos, Eyevance, and RVL. Grant/Research: Johnson & Johnson Vision and Tarsus. Speaker's Bureau: Dompé, Eyevance, and RVL.
The Evolve and The Fundingsland Group staff, planners, and reviewers have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Acufocus, or Johnson & Johnson Vision.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
John W. Kitchens, MD
Sara LeMay, OD
Sustaining Vision: Empowering Optometry for Tomorrow’s Retinal Care
1.00 creditArshad M. Khanani MD, MA, FASRS
Veeral Sheth, MD, MBA, FASRS, FACS
Lejla Vajzovic, MD, FASRS
Sunir J. Garg, MD, FACS, FASRS
Charles C. Wykoff, MD, PhD, FACS
Christina Y. Weng, MD, MBA, FASRS
Mohammad R. Rafieetary, OD, FAAO, FORS, ABO
